4-chloro-N-(4-hydroxynaphthalen-1-yl)-3-nitrobenzenesulfonamide | 420092-79-1

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-chloro-N-(4-hydroxynaphthalen-1-yl)-3-nitrobenzenesulfonamide
• CAS: 420092-79-1
• 化学式: C16H11ClN2O5S
• 分子量: 378.8
• InChiKey: JDYDEJYIVZNWQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• DNA METHYLTRANSFERASE INHIBITORS FOR RETT SYNDROME THERAPY
  申请人：Universität Stuttgart

  公开号：EP3207932A1

  公开（公告）日：2017-08-23

  The invention discloses a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof, for use in treating Rett syndrome. Further disclosed is a pharmaceutical composition comprising a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for use in treating Rett syndrome. Further disclosed is an in vitro method for diagnosing Rett syndrome in a subject comprising the step of analysing DNA methylation in a sample of the subject. Further disclosed is a kit for diagnosing Rett syndrome in a subject in vitro comprising reagents for quantifying a level of DNA methylation in a sample of the subject, wherein an increased level of DNA methylation in the sample compared to a reference value obtained from a reference sample of a healthy individual indicates that the subject has Rett syndrome.

  本发明公开了一种用于治疗雷特综合征的 DNA 甲基转移酶抑制剂或其药学上可接受的盐。进一步公开了一种药物组合物，该组合物包含用于治疗 Rett 综合征的 DNA 甲基转移酶抑制剂或其药学上可接受的盐和药学上可接受的载体。进一步公开了一种诊断受试者 Rett 综合征的体外方法，包括分析受试者样本中 DNA 甲基化的步骤。进一步公开了一种用于体外诊断受试者 Rett 综合征的试剂盒，该试剂盒包括用于量化受试者样本中 DNA 甲基化水平的试剂，其中样本中 DNA 甲基化水平与从健康个体的参考样本中获得的参考值相比增加，表明受试者患有 Rett 综合征。
• AGE-MODIFIED CELLS AND METHODS FOR MAKING AGE-MODIFIED CELLS
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：EP3245303A1

  公开（公告）日：2017-11-22
• STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20210025893A1

  公开（公告）日：2021-01-28

  Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
• [EN] AGE-MODIFIED CELLS AND METHODS FOR MAKING AGE-MODIFIED CELLS<br/>[FR] CELLULES MODIFIÉES PAR L'ÂGE ET PROCÉDÉ DE FABRICATION DE CELLULES MODIFIÉES PAR L'ÂGE
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2016115407A1

  公开（公告）日：2016-07-21

  Provided are age-modified cells and method for making age modified cells by reducing or increasing the level of genomic nucleic acid methylation in the cells. The aging and/or maturation process can be accelerated or reduced and controlled for young, aged, mature and/or immature cells, such as a somatic cell, a stem cell, a stem cell-derived somatic cell, including an induced pluripotent stem cell-derived cell, by reducing or increasing the level of genomic nucleic acid methylation in the cells. Methods described by the present disclosure can produce age-appropriate cells from a somatic cell or a stem cell, such as an old cell, young cell, immature cell, and/or a mature cell. Such age-modified cells constitute model systems for the study of late- onset diseases and/or disorders.
• [EN] STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY<br/>[FR] NIVEAUX STING COMME BIOMARQUEUR POUR L'IMMUNOTHÉRAPIE DU CANCER
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2019195658A1

  公开（公告）日：2019-10-10

  Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.